Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1719-1731

  Swindle, Jason P ^a   Buzinec, Paul ^a   Iorga, Şerban R ^a   Ramaswamy, Krishnan ^b   Panjabi, Sumeet ^b  

^a Innovus   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

ARB; Health outcomes; Healthcare cost; Healthcare utilization; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; QUAN CHARLSON COMORBIDITY SCORE; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ALGORITHMS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051756063     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.589434     Document Type: Article

References (30)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75 (Pubitemid 46360343)
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303: 2043-2050
3. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161:1183-1192 (Pubitemid 32691515)
4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215
5. Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98 (Pubitemid 32321923)
6. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002;15: 28-36 (Pubitemid 35346088)
7. US Department of Health and Human Services. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, National Heart, Lung, and Blood Institute, 2004 Aug
8. Werner C, Poss J, Bohm M. Optimal antagonism of the renin-angiotensin- aldosterone system: do we need dual or triple therapy? Drugs 2010; 70:1215-1230
9. Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther. 2011 May 16;53(1364):39-40
10. US Department of Health and Human Services. Guidance for industry hypertension indication: drug labeling for cardiovascular outcome claims OMB control No 0910-0670. FDA, 2011. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075072.pdf [Last accessed 15 April 2011]
11. Miller LA, Wade R, Dai D, et al. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr Med Res Opin 2010;26:1307-1320
12. Public Law 104-191 1C2. Health Insurance Portability and Accountability Act of 1996. 2009
13. Bureau of Labor Statistics UDoL. Bureau of Labor Statistics, US Department of Labor, Consumer Price Index, Chained Consumer Price Index 1999. 2011
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139 (Pubitemid 41587600)
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
16. Henriksson M, Russell D, Bodegard J, et al. Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertens 2011;25:130-136
17. Russell D, Stalhammar J, Bodegard J, et al. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan. J Clin Hypertens (Greenwich) 2011;13:189-197
18. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus lowdose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-1848
19. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
20. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776 (Pubitemid 37093917)
21. Simons WR, Ram V, Ramaswamy K, et al. Blood pressure outcomes associated with the use of angiotensin II receptor blockers in a primary care electronic medical record database. Poster presented at the American Society of Hypertension. New York, NY, May 2, 2010
22. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407
23. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016
24. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensinconverting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592 (Pubitemid 36204952)
25. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: 995-1003 (Pubitemid 34286536)
26. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906 (Pubitemid 41265663)
27. Zusman RM. Are there differences among angiotensin receptor blockers? Am J Hypertens 1999;12:231S-5S (Pubitemid 30029276)
28. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912 (Pubitemid 32163892)
29. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003;16:123-126
30. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008;68:1239-1272 (Pubitemid 351822113)